In general, six injections spaced at weekly intervals were given. The following quantities of AKR tissues were injected intraperitoneally each time: for thymocytes and marrow, 10 million viable cells; for red blood cells, 0.4 ml of a 30 per cent suspension; for spleen, lymph nodes, and liver, 0.4 mi of a 30 per cent homogenate. For the solid tumors BW5147, $775, and T283, 0.3 ml of a tissue mince was injected subcutaneously.
IA946 leukemia will take when injected intraperitonealJy at high doses into C3HeB/Fe mice (9) . Therefore 100,000 viable L4946 cells were injected intraperitoneally, followed 3 weeks later by 10 million cells aged for 1 week at 3°C, and 2 weeks later by 10 million viable cells. C57BL/6 mice, which reject IA946 leukemia (9) , received 6 weekly intraperitoneal injections of 10 million viable cells. For red cells, thymocytes, spleen, and tumors BW5147, $775, and T283, an additional subcutaneous injection of tissue incorporated in Freund-McDermott adjuvant (11, 12) was given initially. Blood was obtained by cardiac puncture 10 days after the 
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Tissue of origin determined in this study
Non-thymic Thymic
Thymic Non-thymic Thymic Thymic Non-thymic Thymic * Peritoneal cavity of tumor-bearing mouse washed out with 2 ml sterile saline. Then 0.2 ml aliquots of fluid injected intraperitoneally into AKR mice. last injection. For each group of mice, the sera were pooled, inactivated for 30 minutes at 56°C, and stored at --20°C without addition of preservative.
Tumors.--Eight leukemias (Table I ) and osteogenic sarcoma T283 were used; all these tumors originated spontaneously in AKR mice. The leukemias BW5147 and $775 (the latter provided through the courtesy of Dr. G. D. Snell) were converted to ascites form in our laboratory. Sarcoma T283 resisted this conversion.
The five newly derived ascjtes tumors (Table I) were obtained by the transplantation of ceils from spontaneously leukemic AKR mice 7 to 12 months of age. Sterile isotonic saline that contained 100 I.V. penicillin G and 100 #g streptomycin per ml was used to prepare minces or single cell suspensions (see below) of leukemic tissues for intraperitoneal injection into AKR mice. Tumor takes, certified by biological and histological evidence, were obtained in all transplants from leukemic mice.
Cell Suspensions.--For use in immunizations and cytolysis, suspensions of red blood cells (13) , thymic lymphocytes (8) , and tumor cells (12) of mice were prepared as previously described. Cells were kept at 0-5°C unless otherwise specified. In cytolysis and in absorption studies, cells were used within 2 hours after preparation.
Spleens were pressed through a 60-mesh stainless steel screen into modified Locke's solution (12) , and a single cell suspension was prepared by the method of M6ller (14) . Intraperitoneal lymphocytes were washed from the peritoneal cavity with the same buffer, centrifuged at 5°C for 10 minutes at 90 g, and resuspended in fresh buffer. Lymph nodes were suspended in buffer and teased with needles; the lymphocytes that resulted were filtered through an 80-mesh stainless steel screen.
Bone marrow cells were expelled from femurs into modified Locke's solution. Cell dumps were disrupted by suction into a hypodermic syringe. The suspension was centrifuged at 5°C for 10 minutes at 135 g, redispersed in fresh buffer, and filtered through an 80-mesh stainless steel screen.
Compl~n~nt.--Fresh guinea pig serum was absorbed twice for 30 minutes at 3°C with 1/20 volume of packed ~ crythrocytes. The serum was stored at --40°C in sealed 1.5 nd pyrex ampoules. Fresh hamster serum was absorbed twice with 1/20 volume of ~ erythrocytes and three times with 1/10 volume of packed AKR liver homogenate and stored frozen in like manner
(8).
Cytolysis Assay System.--The cytolytic potency of isoantisera was determined in the smallscale assay system previously described in detail (12) . The only change was use Of 100,000 cells per assay tube; also, an incubation period of 1 hour rather th~n 1~ hOurS at 37°C was used for all cells other than the three long-transplanted leukemias. For cytolysis of thymocytes, absorbed hamster serum rather than absorbed guinea pig serum was employed as complement (8) . Cytolytic titers were based on the stained cell count rather than on the deformed cell count, since thereby a closer proportionality between cytolytic titer and cell concentration in the assay system was obtained (12) .
The results for each isoantiserum were plotted to give the cytolytic titer, defined as the final concentration of antiserum ( per cent) that caused 50 per cent staining of intact cells present in the control tube. Factors were determined (see Results) to convert titers obtained in the smallscale assay system to the basis of the regular assay system, in which the cell concentration was 5 million cells/ml (8, 12) . The potency of each isoantiserum was expressed at 100 divided by the cytolytic titer obtained in the regular assay system (13) .
No isoantiserum was tested at a final concentration above 17 per cent. A titer obtained at this level in the small-scale assay system corresponded to a titer of 3.6 X 17 or 61 per cent in the regular assay system, since the latter was less sensitive by a factor of 3.6 (mean value obtained for different cell types, see Results). Thus, depending on the cell types assayed, the minimum cytolytic potency that could be quantified was approximately 100/61 or 1.6.
A potency of 1000 corresponded to a final isoantiserum concentration of 0.1 per cent in the regular assay system, or 0.03 per cent in the small-scale assay system (Fig. 1, top) . Titers were generally sharp and had standard deviations of 20 to 30 per cent when determined in different experiments; deviations were lower when the relative potencies of several antisera were determined in a single experiment (8, 11, 12) . Potencies below approximately 7 were subject to error because of the occasional presence of prozones (Fig. 1, bottom) , and have therefore far less quantitative validity.
If an isoantiserum caused between 40 and 50 per cent cell staining and no prozone was evident, the cytolytic curve (Fig. 1, top) was extrapolated to 50 per cent and a titer was recorded. If staining was between 10 and 40 per cent orif a prozone was evident, the record shows the highest percentage of stained cells above control (per cent a.c.) obtained at any dilution that was tested. Stained cell counts under 10 per cent were not considered significant (compare with reference 15), and the potency of the isoantisernm is stated to lie below the minimum that could be quantified (<2).
When two different types of cells could be distinguished in the cytolytic system (Fig. 2, top) , the titer was read as the final concentration of antiserum that caused 50 per cent staining of the intact cells of a specified type. mice by C3HeB/Fe isoantiserum to AKR thymocytes. Cytolyfie titers were read at the final concentrations of isoantiserum corresponding to the arrows.
Bo#om: Example of a strong prozone. Cytolytic titration of BW5147 leukemia by C3HeB/ Fe isoantiserum to BW5147 leukemia. Bottom: Cytolytic titration of supematants from an absorption experiment. Aliquots of 0.1 ml C3HeB/Fe isoantiserum to AKR thymocytes (in i to 10 dilution) were absorbed with the stated numbers (millions) of AKR thymocytes. The supernatants were diluted 1 to 4 and titrated as shown against AKR thymocytes.
Absorptions.--An adaptation of the method employed by M6Uer (16) and by Amos and coworkers (17) was used. Aliquots of suspensions that contained known numbers of single cells were centrifuged at 5°C for 10 minutes at 220 g and the supematant was removed. Tissues that do not easily yield single cell suspensions were homogenized in modified Locke's solution to 10 per cent on a wet weight basis. After centrifugation at 5°C for 10 minutes at 2000 g, the supernatant was removed and the residue resnspended (or, ff necessary, rehomogenized) in the original volume of buffer. Then suitable aliquots were recentrifuged to give packed residues derived from a known wet weight of intact tissue. These residues were stirred to a slurry-like consistency.
Absorptions were carried out at room temperature. One volume of isoantiserum dilution was added to the requisite quantities of single cells or tissue residues, and mixed every 5 minutes for 30 minutes. Then the tubes were placed in ice water, 3 volumes of cold buffer added, and the contents mixed. Tubes were centrifuged at 5°C for i0 minutes at 700 g or 2400 g, for contents of single ceils or tissue residue, respectively. The supematants were decanted and stored at --20°C. They were subsequently titered by cytolysis against the appropriate cell type.
RESULTS
Assay Systems.--Cytolytic assays: Perhaps the most important criterion for validity of a cytolytic assay is the dependence of cytolytic titer on cell concentration. This criterion was satisfied over specified ranges of cell concentration in the assays previously investigated (8, 11, 12, 18) and in those assays that were tested in this study (Table II) . Ideally, the dependence should be direct proportionality, but in practice this has been attained only in one instance, in work with heterologous antiserum (8) .
Factors were determined to convert fiters obtained with the small-scale assay system to titers based on the regular assay system (12) . For each cell type, two isoantisera were fitered simultaneously in both assay systems and the same experiment was repeated on another day. The small-scale assay system was more sensitive than the regular assay system by a factor of 3.7, 2.7, 2.3, 2.7, 4.0, 5.3, 3.4, 3.7, 4.2, and 3.7, for thymic, lymph node, splenic, intraperitoneal, L4946, BW5147, $775, RA1, RA2, and RA3 cells, respectively.
No isoantiserum tested in this study cytolyzed more than 20 per cent of marrow cells. Even use of a rabbit antiserum against mouse marrow cells, prepared in the same manner as the antiserum against thymocytes (8), did not result in a satisfactory assay system: cytolytic titers were shallow, and the dependence of cytolytic titer on cell concentration was low, even though complementation was adequate. These data suggest that the surface properties of marrow cells, rather than the inadequacy of the assay system, are responsible for the present results with marrow cells.
Quantitative absorption experiments:
A new quantitative method was used to calculate absorption of isoantisera by viable cells and packed tissue residues. The method is illustrated by Table III An isoantiserum was absorbed with a known number of intact cells or with a packed residue derived from a homogenate of a known wet weight of tissue (Table III) . Control absorptions were done with tissues obtained from the strain of mouse (C3Heb/Fe) in which the isoantiserum had been prepared. The supernatant that remained after absorption was titered against AKR thymocytes (Fig. 2 , bottom, and Table III ). The potency of the supernatant was calculated as a percentage of the potency before absorption. When this potency was plotted on logarithmic probability paper against the number of thymocytes used for absorption, a straight line was obtained (Fig. 3 ). This line served as a calibration curve to express the reduction in potency obtained by absorption with any tissue (Table III) in terms of the equivalent number of AKR thymocytes required to produce the same reduction in potency. A slight correction was applied for absorption by control tissues. The absorptive capacity of intact single cells (or of tissue residues) was calculated as a percentage of the absorptive capacity of the same number of AKR thymocytes (or of thymic residue derived from the same wet weight of tissue). Thus in every experiment, AKR thymocytes (or AKR thymic residue) were included to provide a standard of absorption; in addition, a complete calibration curve was occasionally run.
Thymic residues could not be redispersed adequately by manual mixing with isoantiserum during the absorption period. When absorptions were performed with occasional mechanical mixing in a small pyrex homogenizer (MacalasterBicknell Company, Cambridge, Massachusetts, No. 2976), 38 per cent greater absorption of isoantiserum was obtained. Under the latter conditions, residue from a homogenate of 1 mg wet weight of thymus gland absorbed as much isoantiserum as 2.25 million fresh thymocytes (mean value of four determinations).
Positive results in absorption experiments were reproducible if the absorptive capacity exceeded 1.5 per cent. The sensitivity of the method varied with the 0. (Table IV) . Very different results were obtained with isoantisera prepared in a strain that differed in H-2 allele (Table V) .
Contrary to expectation, the C3HeB/Fe isoanfiserum against AKR spleen was more potent in cytolysis of AKR thymocytes than the C3HeB/Fe isoantisenan against AKR thymocytes (Table IV) . Isoanfisera against AKR lymph node cells, washed blood cells, and marrow were approximately one-fifth, one-fifteenth, and one-fifteenth as potent, respectively (Table IV) . These results are partially explained by absorption experiments (Table VI) . Thus, splenic and lymph node lymphocytes did absorb C3HeB/Fe isoantiserum against AKR thymocytes, although not avidly. In general, there was some correlation between the potency of isoantisera prepared against normal tissues and Cytolysis of normal AKR lymphocytes by C57BL/6 isoantisera: This system involves a known difference in H-2 allele and presumably also differences in other histoCompatibility factors (17) . Isoantiserum prepared against spleen gave strong cytolysis of spleen cells but very weak cytolysis of thymocytes; the isoantiserum against thymocytes also gave strong cytolysis of thymocytes but in contrast gave potent cytolysis of spleen cells (Table V) . These are examples of cross-reactions. Nevertheless, the relative potencies of the isoantisera involved in these and other reactions (Table V) give evidence of wide quantitative differences in the surface antigens of thymocytes and of other normal lymphocytes.
C57BL/6 isoantisera failed to differentiate convincingly between lymph node and splenic lymphocytes ( Table V) . The lower potencies shown by isoantisera in their cytolysis of intraperitoneal lymphocytes may indicate a real difference in susceptibility to isoantibodies. Alternatively, lymph node and splenic lymphocytes may be more susceptible to immune cytolysis because their cell surfaces have been injured during physical disruption of the whole organs in preparation of single cell suspensions.
The above explanation cannot account for the resistance of marrow cells to cytolysis by C57BL/6 isoantisera. The absorption datum (Table VI) , the low potencies of isoantisera prepared against marrow cells (Tables IV and V) , and the data obtained with heterologous antiserum (see above) suggest a different explanation. This is, that marrow cells possess a relatively low concentration of surface isoantigens.
Cytolysis of AKR leukemias by C3HeB/Fe isoantisera:
In contrast to the selective cytolysis of normal AKR tissues by C3HeB/Fe isoantisera (Table IV) , four out of six AKR leukemias were highly sensitive to C3HeB/Fe isoantisera (Table VII) . Isoantisera to thymocytes, spleen, and L4946 leukemia were the most potent. The relative potencies of C3HeB/Fe isoantisera were similar not only for cytolysis of three of the four highly sensitive leukemias, but also for cytolysis of normal thymocytes (Table VIII) . This raises the possibility that the various C3HeB/Fe isoantisera all possessed antibodies directed against the same antigen (or group of antigens). Absorption studies (Table VI) support the suggestion that the same antigen was present in different concentration or spacial arrangement on the surface of normal thymocytes and of leukemias with high absorptive capacities.
Cytolysis of A KR leukemias by C57BL/6 isoantisera: Cytolysis of normal AKR
cells by C57BL/6 isoantisera revealed striking differences among three cell types: first, thymocytes; secondly, lymph node, splenic, and intraperitoneal lymphocytes; and thirdly, marrow cells (Table V) . Cytolysis of AKR leukemias by the same isoantisera shows that certain leukemias reacted almost exactly like one of these normal cell types (Table IX) . For instance, IA946 leukemia (Table IX) reacted similarly to normal lymph Tables IV and VII. node, splenic, or intraperitoneal lymphocytes (Table V) ; the chief differences were somewhat stronger cytolysis of IA946 ceils by isoantisera against washed blood ceils and marrow. Absence of cytolytic potencies in excess of 2 for any C3HeB/Fe isoantiserum assayed against L4946 cells (Table VII) again indicates a strong similarity with non-thymic lymphocytes (Table IV) . Further, when the absorptive capacity of IA946 cells for a C3HeB/Fe isoantiserum (Table VI) is calculated on the basis of unit cell surface (19) , it becomes 4.8 per cent or essentially equal to that of splenic lymphocytes. 1 The above data strongly support the concept that IA946 leukemia is non-thymic in origin.
Similar considerations indicate that leukemia RA1 is non-thymic in origin (Tables VI, VII , and IX). In contrast, leukemias BW5147, $775, RA2, and RA3 1200 fresh AKR lymphocytes and L4946 cells had mean diameters of 6.1 and 10.3 #, which corresponded to mean spherical surface areas of 121 and 333 ~t 2, respectively. reacted similarly to thymocytes with C3HeB/Fe isoantisera (Tables IV, VII , and VIH), and their absorptive capacities for such isoantisera were high (Table VI) . However, their cytolytic reactions with C57BL/6 isoantisera (Table  IX) were more similar to those of splenic than of thymic lymphocytes (compare with Table V ). The data suggest that these leukemias developed from the same stem cell as thymocytes, but possess higher concentrations of the antigens that correspond to the H-2 k and H-2 k' allele, than do thymocytes. Detailed data on immune cytolysis of leukemias RA4 and RA5 are not presented here. C3HeB/Fe isoantisera cytolyzed only RA5, while C57BL[6 isoantisera cytolyzed both leukemias. Absorption experiments (Table VI) showed the same sharp quantitative distinction and the same correlation with cytolysis by C3HeB/Fe isoantisera that was found for the other leukemias. These data suggest that leukemias RA4 and RA5 are respectively non-thymic and thymic in origin, and further strengthen the close correlation between the results of cytolysis and absorption experiments.
Analysis of mixtures of normal and leukemic lymphocytes: Various C3HeB/Fe isoantisera caused strong cytolysis of thymus-derived leukemias (Table VII) , but had no effect on normal intraperitoneal lymphocytes (Table IV) . Hence, C3HeB/Fe isoantisera could be used to determine the percentage of normal and thymus-derived leukemic cells in peritoneal exudates (Fig. 2, top) . This method may prove to be a useful tool for study of the biology of recently derived AKR leukemias. Antigenic stability of newly derived leukemia: Leukemia RA3 was subjected to immune cytolysis experiments both in its first and in its fifth transplant generation. Isoantisera prepared against normal tissues showed lower cytolytic potencies for cells of the fifth transplant generation, while isoanfiserum against L4946 tumor showed higher potencies (Tables VII, and IX) . However, the changes were too small to constitute definite evidence for a change in content of antigens between transplant generations 1 and 5.
The original transplant of leukemia RA1 was made separately from thymus and from spleen of the same AKR mouse, and the tumors that resulted were carried separately. Ten C57BL/6 isoantisera of varying cytolytic potencies, when tested against cells of the fifth transplant generation of both tumor lines, gave results that corresponded closely. These results suggest that the two leukemic tissues that were originally transplanted contained the same type of leukemic lymphocyte.
Presence of the AKR thymic antigen in normal AKR tissues:
The AKR thymic antigen was present in high concentration not only in thymus but also in all adult nervous tissues that were examined (Table X) . Low levels of the antigen were present in adult lymph node lymphocytes, splenic lymphocytes, appendix and lung (Tables VI and X ). The antigen was almost fully developed in the thymus of newborn mice (Tables VI and XI) ; in contrast, neonatal brain contalned less than 2 per cent of the antigen found in adult brain (Table X) , and neonatal spleen contained less of the antigen than adult spleen (Table VI) .
Presence of AKR thymic antigen in other strains of mice: RF thymocytes were
cytolyzed by C3HeB/Fe isoantiserum against AKR thymocytes at a potency similar to that effective against the homologous cells (Table XI) . RF splenic lymphocytes, in common with AKR splenic lymphocytes, were not cytolyzed by this isoantiserum. The thymocytes of other strains that were tested gave no indication of cytolysis (Table XI) . Absorption experiments with thymocytes of various strains were equally clear-cut. Thymocytes from RF mice absorbed almost as much of the C3HeB/Fe isoantiserum as did AKR thymocytes. In contrast, thymocytes from other strains of mice did not absorb significant quantities of isoantibody (Table XII) .
The above results are consistent with the presence of the AKR thymic antigen on RF thymocytes in a quantity similar to that on the homologous cells.
Thymocytes from the other strains tested either lack this antigen, or possess less than one-hundredth of the amount present on the surface of AKR or RF thymocytes (Tables XI and XH) . In tissues of RF mice that were tested, the distribution of the thymic antigen was similar to that in tissues of AKR mice (Table X) .
Distribution of C31~eB/Fe thymic antigen: Most experiments described above
were done with C3HeB/Fe isoantisera to AKR tissues. Experiments described below were done with the inverse isoantisera. In particular, AKR isoantisera to C3HeB/Fe thymocytes and to C3HeB/Fe splenic lymphocytes were used, since isoantisera to these tissues were most potent in the inverse situation (Table IV) .
The AKR isoantisera cytolyzed thymocytes from all mouse strains tested except AKR and RF (Table XI) . The AKR isoantisera were inactive in cytolysis of splenic lymphocytes from adult mice of strains C3HeB/Fe, A, C57BL, and C57BL/6; of lymph node lymphocytes from adult mice of strains C3HeB/Fe, A, and C57BL/6; and of leukemia EL4 of C57BL mice. These results parallel those obtained with the inverse isoantisera (Table IV) . 
Data obtained by absorption of an AKR isoantiserum with different numbers of intact C3HeB/Fe thymocytes gave a straight line parallel to that in Fig. 3 . This line was used as caliberation curve for the quantitative determination of the absorptive capacities of intact cells or tissue residues.
An AKR isoantiserum to C3HeB/Fe splenic lymphocytes was absorbed with intact cells from strains that possessed the C3HeB/Fe thymic antigen. Relative to absorption by adult C3HeB/Fe thymocytes, the absorptive capacities of these cells were as follows: thymocytes from C57BL/6, C57BL, and neonatal CSTBL mice, 88, 74, and 74 per cent respectively; lymph node lymphocytes from C3HeB/Fe, C57BL/6, and C57BL mice, 19, 11, and 16 per cent respectively; splenic lymphocytes from the same three strains, 12, 5.3, and 9.8 per cent respectively; neonatal splenic lymphocytes of C57BL and ICR Swiss mice, 2.7 and 2.3 per cent respectively; and EL4 leukemia of C57BL mice, 11.4 per cent, or 1.7 per cent if calculated on the basis of equal cell surface area rather than equal cell number. 2 These results are similar to those obtained with an inverse isoantiserum ( Table VI) .
The same AKR isoantiserum was absorbed with tissue residues from strains C3HeB/Fe and CS7BL/6. Since results for the two strains were closely similar, they have been averaged: the absorptive capacity of thymus, brain, appendix, lung, liver, and kidney was 100, 122, 3.0, 1.3, 0.65, and 0.49 per cent respectively. Neonatal brain of C57BL, ICR Swiss, and A mice averaged 2.4 per cent of the absorptive capacity possessed by adult brain of these three strains. Again, these data resemble those obtained with an inverse isoantiserum (Table X) .
DISCUSSION
Gorer and coworkers reported three X antigens present specifically in EL leukemias of C57BL mice: EIA X, EL6 X, and EL8 X. Since some EL leukemias arose in thymus, they searched for X antigens in that tissue, but were not successful. EL leukemias could not be cytolyzed by isoantibodies to the X antigens (2) .
In contrast, isoantibodies to the AKR or C3HeB/Fe thymic antigens cytolyzed thymocytes that possessed either of these antigens (Table XI) . Further, EIA leukemia did not absorb measurable quantities of an isoantiserum to AKR thymus, and absorbed less isoantiserum to C3HeB/Fe thymus than did normal splenic lymphocytes of strain C57BL. These data indicate that both the present thyrnic antigens are distinct from EL4 X and cast doubt on identity with EL6 X or EL8 X.
Old, Boyse, and Stockert reported presence of the LT antigen in some C57BL leukemias (4), reminiscent of Gorer's results (2, 20) . However, the LT antigen was distinct from EL4 X. Their findings include absence of the LT antigen in s The mean diameter of EL4 cells was 15.6 ~.
normal C57BL thymus, and presence of the LT antigen in A and C58 thymus (4) .
These latter data clearly distinguish the LT antigen both from the AKR and from the C3HeB/Fe thymic antigen (Table XI) . More recent work (21, 22) has confirmed the differentiation between the LT and AKR antigens. Since the LT antigen is present in A but not in C57BL thymus (4) , while the C3HeB/Fe thymic antigen is present in both strains (Table XI) , it appears that more than one thymic antigen can be present in thymus of a single inbred mouse strain.
The AKR and C3HeB/Fe thymic antigens could represent previously unrecognized expressions of known mouse histocompatibility (H) factors. Comparison of the present Table XI with Table 10 of Amos et al. (17) excludes association of either antigen with any of the six known mouse histocompatibility factors H-1 to H-6. Moreover, since thyrnocytes of female AKR or C3HeB/Fe mice possess a full complement of the respective thymic antigens, Y-linked histocompatibility antigens (23) are not implicated.
Amos et al. have suggested that apparently new serologically determined mouse antigens be first designated by Greek letters (17) . In line with this suggestion, the names 0-AKR and 0-C3HeB/Fe are proposed for the two thymic antigens described here and (in the case of the AKR antigen) previously (9) . When the precise relationship of these antigens to the new mouse antigens presently under investigation by Snell (24) and others (21) has been determined, perhaps a different nomenclature will be more appropriate.
The disproportionately high antibody response to viable IA946 cells (Table  IV) , relative to the absorption of isoantibody by these ceils (Table VI) , requires explanation. At low doses of antigen, antibody response is loosely correlated with the quantity of antigen injected (25) . More important, the initial multiplication of viable tumor cells in an incompatible host provides a powerful stimulus to antibody response (24, (26) (27) (28) .
Lymphocytes resist immune cytolysis, unless a minimum concentration of sites that can bind the relevant antibodies is present on their surfaces (14, 19, 29, 30) . If this minimum is exceeded and the potencies of the isoantisera are sufficiently high to avoid prozone formation, then immune cytolysis provides clear-cut, quantitative evidence of an immune reaction. However, present results support the conclusion of M611er (30) , that absorption experiments are more sensitive.
The LT antigen is present in certain C57BL leukemias but absent from thymus and other normal C57BL tissues (4); one possible explanation is that the LT antigen is latent in this strain. Therefore, the high content of the 8-AKR antigen in certain AKR leukemias (Table VI) does not necessarily prove that these leukemias originated in thymus; they may have originated in a cellular precursor of thymocytes. This latter possibility is supported by the difference in the spectrum of cytolytic reactions of C57BL/6 isoantisera with thymocytes and with leukemias that possessed a high content of 0-AKR, such as $775 and RA3 (Tables V and IX) . In contrast, the cytolytic reactions with C57BL/6 isoantisera strengthen the evidence that leukemias with low contents of the 0-AKR antigen were of non-thymic origin.
The 0-AKR and the 0-C3HeB/Fe antigens had an inverse distribution in eighteen mouse strains (Table XI) . Both antigens had a similar distribution in tissues of the strains that were tested. There were no exceptions to these two rules.
It was unexpected to find the same antigen (either 0-AKR or 0-C3HeB/Fe) present in high amounts in thymus and in nervous tissue of each of the six strains tested. However, neonatal brain possessed only between 1.5 and 2.8 per cent of the content of antigen found in adult brain in the four strains studied. In contrast, the antigen was almost fully developed in neonatal thymus.
The above results suggest that 0-AKR and 0-C3HeB/Fe antigens originated either in the thymus or in closely related cellular precursors. The concept that an immunological maturation of mouse brain takes place after birth is new. Present indications of a close immunological relation among thymus, leukemias, and nervous tissues require further investigation.
The low but definite content of the 0-AKR or 0-C3HeB/Fe antigen in spleen, lymph nodes, appendix, and lung of the strains studied may have been due either to presence of the respective antigens on cells of these tissues or to migration of thymocytes into the tissues. It remains to be determined whether the development of 0-isoantigens in neonatal spleen parallels the development of H-2 isoantigens, which has been well documented by the M611ers (14, 16, 19, 30) . The present data fit the concept that thymocytes migrate to neonatal spleen and there induce differentiation of lymphoblasts to immune competent cells (31) (32) (33) (34) (35) .
SUMMARY
A clear-cut serological differentiation between AKR lymphocytes of thymic and non-thymic origin is reported: these two cell types are antigenically distinct.
In newborn mice, the AKR thymic antigen was found at a high concentration only in thymus. In adult mice, the antigen was present at a high level in thymus, all nervous tissues tested, and some leukemias. It was present at much lower levels in lymph node lymphocytes, splenic lymphocytes, appendix, lung, and certain other leukemias, which appeared to be of non-thymic origin. The AKR thymic antigen was present at a high level in thymus and nervous tissues of RF mice, but was absent from thymocytes of sixteen other mouse strains.
These sixteen strains possessed the C3HeB/Fe thymic antigen. The distribution of this antigen in neonatal and adult tissues of the strains tested was s~m~lar to that of the AKR thymlc antigen in AKR mice. No exceptions were found.
